Physician profile
William C Brown
NPI 1396741088
$4,198.80
in general payments reported to CMS, 2019-2025
30 companies · $247 in 2025
The $247 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $874 · 2020: $894 · 2021: $1,075 · 2022: $430 · 2023: $420 · 2024: $259 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $876 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $876.18 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $470.47 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $430.57 | 2019-2025 | Airsupra |
| Allergan, INC. | $352.42 | 2020-2021 | |
| Amarin Pharma, INC. | $304.28 | 2019-2022 | |
| Pfizer INC. | $294.46 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.04 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $268.32 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $247.41 | 2019-2025 | Ozempic, Rybelsus |
| Currax Pharmaceuticals LLC | $170.37 | 2020-2025 | Nexletol, Contrave |
| Lilly USA, LLC | $167.97 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $150.61 | 2020-2021 | |
| Integra Lifesciences Corporation | $126.74 | 2019 | |
| Novartis Pharmaceuticals Corporation | $115.34 | 2019-2023 | |
| Esperion Therapeutics, INC. | $104.06 | 2020-2021 | |
| Medtronic USA, INC. | $101.51 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $87.02 | 2019-2021 | |
| Abbott Laboratories | $73.88 | 2023-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $55.78 | 2023-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $54.62 | 2019 | |
| Almatica Pharma LLC | $46.34 | 2021-2022 | |
| Eisai INC. | $43.30 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $40.65 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $39.28 | 2021 | |
| Amgen INC. | $39.07 | 2024 | Repatha, Otezla |
| Boston Scientific Corporation | $31.41 | 2025 | Watchman Access System |
| Biohaven Pharmaceuticals, INC. | $29.95 | 2020-2021 | |
| Daiichi Sankyo INC. | $25.03 | 2023 | Injectafer |
| Abbvie INC. | $15.21 | 2023 | Ubrelvy |
| Idorsia Pharmaceuticals US INC | $13.45 | 2022 | |
| Dexcom, INC. | $13.24 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.